Omega-3 fatty acids improve quality of life, outcomes in cancer
the ONA take:
According to a new study published online ahead of print in the Journal of Parenteral and Enteral Nutrition (JPEN), researchers at the University Hospitals of Leicester in the United Kingdom have found that the addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
For the study, researchers enrolled 150 patients with advanced pancreatic cancer. Participants received gemcitabine 1,000 mg weekly followed by up to 100 g of omega-3 rich lipid emulsion for 3 weeks followed by 1 rest week. Patients received up to six cycles until disease progression, unacceptable toxicity, patient request, or death.
Results showed that patients who received omega-3 fatty acids experienced an improvement in response activity and disease stabilization rates, a reduction in liver metastases volume, and improved quality of life.
The findings suggest that further investigation is warranted to evaluate the addition of omega-3 fatty acids with a chemotherapy agent in a randomized phase III trial.
Addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
- Clinical Trials May Benefit Oncology Patients
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|